← Back

STERIS plc

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

Price · split & dividend adjusted
News & notes moving STE
STE▲

STERIS Commits $600 Million to Chemistry Center of Excellence

STERIS plc is making its largest-ever investment in a single manufacturing site with a $600 million formulated chemistries Center of Excellence in North Carolina. The project will combine manufacturing, research and development, and distribution for formulated chemistries used across Healthcare and Life Sciences, which management said generate more than $700 million in revenues and are high-growth, high-margin and highly regulated. The center will include two facilities totaling 600,000 square feet, with a phased opening in two to three years beginning with distribution, followed by work transfers from existing chemistry sites in St. Louis, Missouri, and Plymouth, Minnesota. STERIS expects the project to generate a return on invested capital above 10% within three to five years of opening, with about $75 million of additional capital spending in fiscal 2027, roughly $350 million in fiscal 2028 and the remaining $175 million in fiscal 2029. Fiscal 2027 capital expenditures are now expected to be about $450 million, up from the prior $375 million outlook, and free cash flow guidance was reduced to about $800 million from $850 million, while the company also expects $55 million to $70 million of pretax restructuring charges tied to the consolidation plan.
STE ▲
Zacks Investment Research·5dRead more ▾
STE

Surgical Equipment Stocks Beat Q2 Revenue Estimates by 1.6%

Surgical equipment and consumables stocks tracked by StockStory delivered a strong second quarter, with group revenues beating analysts' consensus estimates by 1.6%. STERIS reported revenues of $1.49 billion, up 7.3% year on year, in line with expectations but with the weakest performance against analyst estimates of the group. Solventum posted revenues of $2.21 billion, up 2.2% year on year, outperforming expectations by 2.5% and delivering the biggest analyst estimate beat among its peers. Zimmer Biomet reported revenues of $2.18 billion, up 4.8% year on year, exceeding expectations by 2%, while CONMED reported revenues of $343.5 million, flat year on year, beating expectations by 1.8%. BD reported revenues of $4.98 billion, up 5.4% year on year, topping expectations by 2%.
BDX ▲CNMD ▲SOLV ▲STE ZBH ▲
StockStory·10dRead more ▾
STE▼

95% of healthcare firms beat EPS estimates this week

Twenty-one out of 22 healthcare companies that reported quarterly earnings this week delivered better-than-expected earnings per share, with Pfizer, Merck, and Eli Lilly among the major names topping Wall Street forecasts. Pfizer posted adjusted EPS of $0.77 on revenue of $15.03 billion and raised its full-year revenue guidance by $500 million at the midpoint to a range of $60.5 billion to $62.5 billion. Merck reported an adjusted loss of $0.13 per share while revenue rose 5.1% year over year to $16.61 billion, driven by Keytruda sales of $8.4 billion. Eli Lilly’s adjusted EPS jumped roughly 33% to $8.38 on revenue of $23 billion, powered by its GLP-1 portfolio including Zepbound and Mounjaro. Vertex Pharmaceuticals was the only firm to miss earnings estimates, while Zoetis and STERIS fell short on revenue.
LLY ▲MRK ▲PFE ▲VRTX ▼STE ▼ZTS
Seeking Alpha·18dRead more ▾
STE▲

STERIS Reports 7% Revenue Growth in Fiscal 2027 First Quarter, Announces Restructuring Plan

STERIS announced fiscal 2027 first quarter revenue increased 7% to $1.5 billion, with constant currency organic revenue growth of 6%. As reported diluted earnings per share rose to $2.04 from $1.79 a year earlier, while adjusted diluted EPS climbed to $2.59 from $2.34. The company also unveiled a targeted restructuring plan tied to a new Formulated Chemistries Center of Excellence in North Carolina, which will consolidate manufacturing and distribution and lead to the closure of facilities in St. Louis, Missouri, and Plymouth, Minnesota. STERIS expects to incur total pre-tax restructuring charges of approximately $55 million to $70 million, with completion anticipated during fiscal 2030. The company reiterated its full-year fiscal 2027 outlook for revenue growth of 7-8% and adjusted EPS of $11.10 to $11.30, while raising its capital expenditure forecast to approximately $450 million and lowering its free cash flow expectation to approximately $800 million.
STE ▲
GlobeNewswire·21dRead more ▾
STE

Zimmer Biomet Leads Surgical Equipment Earnings with 9.3% Revenue Growth

Zimmer Biomet reported first-quarter revenues of $2.09 billion, up 9.3% year on year, making it the fastest-growing company among five surgical equipment and consumables stocks tracked. The result exceeded analysts' expectations by 0.9%, and the company also beat earnings per share estimates and full-year EPS guidance. CONMED posted revenues of $317 million, down 1.3% year on year but beating estimates by 2.1%, the largest beat in the group. STERIS reported $1.59 billion in revenues, up 7.3% and in line with expectations, while BD's revenues rose 5.2% to $4.71 billion, topping estimates by 0.8%. Solventum's revenues declined 3.1% to $2.01 billion, surpassing estimates by 1.9% but recording the slowest revenue growth among the peers.
ZBH ▲CNMD ▲SOLV ▼BDX STE
Yahoo Finance·30dRead more ▾
STE▼

STERIS Stock Declines 20.4% Over Six Months Amid Revenue and Margin Concerns

STERIS shares have fallen 20.4% over the past six months to $202.39, prompting a reassessment of the stock. Analysts at StockStory cite three reasons to avoid the company: annualized revenue growth of 7.5% over the last two years has decelerated below its five-year trend, adjusted operating margin has remained flat at 23.3% over the trailing twelve months despite revenue gains, and its five-year average return on invested capital stands at a mediocre 5.3%. The stock now trades at 17.9 times forward earnings, which is considered fair but not compelling given the lack of confidence in the business.
STE ▼
StockStory·69dRead more ▾
© 2026 MarketDXAsset